Massive 3,000-Patient study tracks Real-Life impact of new breast cancer drugs
NCT ID NCT07243002
Summary
This study aims to learn how well two newer breast cancer drugs, ribociclib and abemaciclib, work for people in everyday medical care, not just in controlled trials. It will follow 3,000 adults with a specific type of early-stage breast cancer to see how long they stay cancer-free, how they manage side effects, and how treatment affects their daily life and work. Researchers will look at past medical records and ask patients directly about their experiences to get a complete picture.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGLondon, SW3 6JJ, United Kingdom
Conditions
Explore the condition pages connected to this study.